James Novotny, Jr., Milford, NJ (US); Nils Lonberg, Woodside, CA (US); Cyrus Hedvat, New York, NY (US); Raphael Clynes, West Nyack, NY (US); Darren Locke, Bordentown, NJ (US); John P. Cogswell, Yardley, PA (US); Jeffrey Jackson, Schwenksville, PA (US); Christopher Harbison, Hamilton, NJ (US); and Robin Edwards, Newtown, PA (US)
Assigned to Bristol-Myers Squibb Company, Princeton, NJ (US)
Appl. No. 16/616,574
Filed by Bristol-Myers Squibb Company, Princeton, NJ (US)
PCT Filed May 30, 2018, PCT No. PCT/US2018/035134 § 371(c)(1), (2) Date Nov. 25, 2019, PCT Pub. No. WO2018/222718, PCT Pub. Date Dec. 6, 2018.
Claims priority of provisional application 62/582,178, filed on Nov. 6, 2017.
Claims priority of provisional application 62/555,176, filed on Sep. 7, 2017.
Claims priority of provisional application 62/513,813, filed on Jun. 1, 2017.
Claims priority of provisional application 62/512,648, filed on May 30, 2017.
Prior Publication US 2021/0261666 A1, Aug. 26, 2021
1. A method of treating a malignant tumor in a human patient, comprising administering an immunotherapy to the patient, wherein the immunotherapy comprises a LAG-3 inhibitor and a PD-1 pathway inhibitor, and wherein at least about 1% of nucleated cells in a sample of the patient's tumor are tumor-infiltrating lymphocytes expressing LAG-3.